Kymera Therapeutics, INC 8-K filings

Kymera Therapeutics reported strong Q2 2026 results, highlighted by accelerated trial enrollment for KT-621, significant milestone payments from partnerships, and a cash runway extending into 2029.

Kymera Therapeutics announced the appointment of Dr. Terence Rooney as Chief Medical Officer, succeeding Dr. Jared Gollob who is retiring.

Kymera Therapeutics has completed enrollment in its Phase 2b BROADEN2 trial for KT-621 six months ahead of schedule.

Kymera Therapeutics shareholders re-elected four Class III directors and ratified the appointment of Ernst & Young LLP.

Kymera Therapeutics announced the resignation of its Chief Operating Officer, Jeremy Chadwick, who will transition to an advisory role until November 2026.

Kymera Therapeutics reported Q1 2026 financial results, highlighting strong collaboration revenue and providing updates on its STAT6 and IRF5 degrader programs, with significant cash reserves extending runway into 2029.

Kymera Therapeutics, Inc. has amended its bylaws to designate federal district courts as the exclusive forum for Securities Act and Exchange Act claims.

Kymera Therapeutics establishes a new at-the-market equity offering program for up to $500 million with TD Cowen and registers a significant resale of shares by institutional investors.

Kymera Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting pipeline progress for its STAT6 and IRF5 degrader programs and a strong cash position.

Kymera Therapeutics announced its preliminary cash balance of $1.6 billion as of December 31, 2025, and detailed its key clinical and preclinical objectives for 2026, emphasizing its oral immunology pipeline.

Kymera Therapeutics successfully priced an upsized public offering of 8,050,000 common shares at $86.00 each, raising approximately $656.1 million in net proceeds to advance its clinical pipeline and extend its cash runway into 2029.

Kymera Therapeutics announced positive Phase 1b results for its oral STAT6 degrader KT-621 in atopic dermatitis, demonstrating deep STAT6 degradation and robust clinical improvements comparable to Dupilumab.

Kymera Therapeutics announced positive Phase 1b clinical trial results for its oral STAT6 degrader KT-621 in moderate to severe atopic dermatitis patients, showing strong efficacy and a favorable safety profile.

Kymera Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical pipeline, including progress for KT-621 and KT-579 programs.

Kymera Therapeutics announced the retirement of its Chief Legal Officer, Ellen Chiniara, and the appointment of Brian Adams as her successor, effective September 3, 2025.

Kymera Therapeutics announced its second quarter 2025 financial results, highlighted by positive Phase 1 data for KT-621, a new strategic partnership with Gilead, and an extended cash runway into late 2028.

Kymera Therapeutics, a clinical-stage biopharmaceutical company, has successfully priced a public offering of common stock and pre-funded warrants, raising approximately $250.8 million to advance its clinical pipeline and extend its operational funding into mid-2028.

Kymera Therapeutics, Inc. announced the successful election of its Class II director nominees, the advisory approval of named executive officer compensation, and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Shareholders.

Kymera Therapeutics announced that its partner Sanofi will advance the next-generation IRAK4 degrader KT-485 into clinical studies, leading to a $20 million milestone payment and potential for up to $975 million in future milestones, while discontinuing development of KT-474.

Kymera Therapeutics has entered into an exclusive option and license agreement with Gilead Sciences to develop novel oral molecular glue CDK2 degraders for broad oncology treatment, including breast cancer, with potential payments up to $750 million.

Kymera Therapeutics, Inc. announced compelling Phase 1 healthy volunteer results for its investigational oral STAT6 degrader, KT-621, demonstrating potent and complete STAT6 degradation and a favorable safety profile, positioning it as a potential oral alternative to injectable biologics for immuno-inflammatory diseases.

Kymera Therapeutics, Inc. reported highly positive first-in-human Phase 1 clinical trial results for KT-621, an investigational oral STAT6 degrader, demonstrating robust STAT6 degradation, favorable safety, and promising Th2 biomarker reductions comparable or superior to dupilumab.

Kymera Therapeutics reports its Q1 2025 financial results, highlights pipeline progress, and introduces a new oral IRF5 degrader program, KT-579, for immuno-inflammatory diseases.

Kymera Therapeutics approved the grant of performance stock units (PSUs) to key employees, including named executive officers and the management team, effective March 3, 2025.

Kymera Therapeutics reports its Q4 and full-year 2024 financial results, highlighting a strong cash position and progress in its STAT6, TYK2, and IRAK4 degrader programs.

Kymera Therapeutics outlines its key objectives for 2025, focusing on advancing its portfolio of oral immunology programs and presenting at the J.P. Morgan Healthcare Conference.

Kymera Therapeutics reports third quarter 2024 financial results, highlights clinical trial progress, and announces a strategic shift towards immunology.

Kymera Therapeutics has launched a public offering to raise $225 million through the sale of common stock and pre-funded warrants.

Kymera Therapeutics reported its second quarter 2024 financial results, highlighted by a strong cash position and advancements in its clinical programs.

Kymera Therapeutics, in collaboration with Sanofi, will expand its Phase 2 trials for KT-474 in Hidradenitis Suppurativa and Atopic Dermatitis after a positive review of preliminary safety and efficacy data.